User:Mr. Ibrahem/Ticlopidine

Mr. Ibrahem/Ticlopidine

Clinical data
Trade names	Ticlid
AHFS/Drugs.com	Monograph
MedlinePlus	a695036
License data	US DailyMed: Ticlopidine
Pregnancy category	AU: B1
Routes of administration	By mouth
Drug class	Platelet aggregation inhibitor
Legal status
Legal status	US: ℞-only EU: Rx-only In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	>80%
Protein binding	98%
Metabolism	Liver
Elimination half-life	12 hours (single dose) 4–5 days (repeated dosing)
Excretion	Kidney and fecal
Identifiers
IUPAC name 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
Chemical and physical data
Formula	C14H14ClNS
Molar mass	263.78 g·mol−1
3D model (JSmol)	Interactive image
SMILES Clc1ccccc1CN3Cc2c(scc2)CC3
InChI InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2 Y Key:PHWBOXQYWZNQIN-UHFFFAOYSA-N Y
(verify)

Ticlopidine, sold under the brand name Ticlid, is a medication used to prevent stroke and coronary stent blockage. It is only used in those who cannot take aspirin and when other options are not available. It is taken by mouth.

Common side effects include rash, low neutrophils, purpura, liver problems, and loss of appetite. Due to side effects clopidogrel, ticagrelor, or prasugrel are generally used instead. It is a platelet aggregation inhibitor, specifically a adenosine diphosphate receptor inhibitor.

Ticlopidine was patented in 1973 and approved for medical use in 1978. It was approved for medical use in the United States in 1991. It is not commercially available in the United States as of 2021.